Home » Newsletters » BioWorld Science

BioWorld Science

June 14, 2019

View Archived Issues

DDR inhibitor could boost chemo

RNA triad prevents dialysis-induced fibrosis

Experimental malaria proteasome inhibitors have each other's backs

IFX-1 enters phase II study in patients with pyoderma gangrenosum

ModernaTX initiates first-in-human study of mRNA-3704

Abeona Therapeutics presents first data on ABO-401 gene therapy

Corvidia opens phase II study of ziltivekimab to reduce inflammation in chronic renal disease

FDA accepts MetVital's IND for phase IIa trial of AEO for glioblastoma multiforme

Favorable pharmacokinetics seen with ELX-02 in phase I studies

Phase I trial of BN-Brachyury vaccine in advanced solid tumors

EC approves conversion of the conditional approval into standard marketing authorization for Pixuvri

Desmetramadol provides the same safety and analgesia as tramadol without metabolic liabilities

Initial phase I data presented for ETX-0282

H3B-6527 demonstrates early signal of clinical activity in patients with HCC

Flumatinib shows superiority over imatinib in phase III study in patients with CML

NKTR-358 demonstrates safety, tolerability and promotes regulatory T-cell responses

VitNovo's VN-B101 in combination with standard diabetes medication improves glycemic control in mice

Alzheimer's protein links plaques to cell death in mice

Synlogic, Ginkgo Bioworks enter collaboration to accelerate synthetic biotic medicine development

BioMarin Pharmaceutical patents UGT8 inhibitors

PolyPEPI-1018 cancer vaccine safe and well tolerated in colorectal cancer patients

Mersana Therapeutics presents new antibody-drug conjugates

Biogen discloses NFE2L2 activators

Panorama Research describes ionotropic glutamate GluN2B receptor antagonists

Sorrento Therapeutics patents CD38-targeting CAR constructs

AbCellera to support Gilead in discovery of therapeutic antibodies for infectious diseases

FDA approves trastuzumab biosimilar Kanjinti

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...